Home » Our Services » Clinical Services » Haematology » Meet the Team » Consultant Staff

Consultant Staff

The head of the department is Dr Rachel Hall, Consultant Haematologist.

Dr Rachel Hall, Consultant Haematologist BSc, MBBS, MRCP, FRCPath

Clinical interests::

  • Myeloma: runs a dedicated myeloma clinic and has a specialist myeloma nurse.
  • Extensive myeloma Trials Portfolio in conjunction with Dr Helen McCarthy.
  • Member of the UK Myeloma Forum.
  • Lymphoma.
  • Autologous stem cell transplantation and acute leukaemia.


1. Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry. Biology of Blood and Marrow Transplantation, In Press.

2. Myeloma Matters Vol8 Issue 5 ‘Autologous stem cell transplantation in Myeloma’ Sept 09

3. Interim analysis of a study to investigate safety, QOL, patient satisfaction and preference with domiciliary versus day ward administration of bortezomib. Haematologica 2011 96 (S1)

Dr Joseph Chacko, Consultant Haematologist, MBBS, MD, MRPCP, FRCPath

Clinical interests:

  • Myeloid malignancies including acute myeloid leukaemia, myelodysplastic syndromes (MDS) and myeloproliferative disorders.
  • Lymphoma.
  • Higher specialist training in Stem Cell Transplantation. Runs a dedicated transplant clinic and has a transplant specialist nurse.
  • Coagulation.


1. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. British Journal of Haematology 2011, 154 (4): 521-524

2. UK experience of azacitidine therapy in patients with myelodysplastic syndromes. Leukaemia Research 2011, 35 (S1), 177a.

3. Counting the cost of thrombophilia testing in a district general hospital. Journal of Haematology 2011, British Journal of Haematology 2011,153 (S1), 211a.

Dr Sally Killick, Consultant Haematologist, MBBS, MD, FRCP, FRCPath

Clinical interests:

  • Myelodysplastic syndromes (MDS).
  • Member of the UK MDS Executive Committee.
  • Member of the NCRI MDS trials subcommittee.
  • Extensive portfolio of clinical trials for MDS and elderly AML with Dr Joseph Chacko.
  • Aplastic Anaemia.
  • Lymphoma.


1. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. British Journal of Haematology 2011, 154 (4): 521-524

2. Guidelines for the diagnosis and management of Aplastic Anaemia. British Journal of Haematology 2009,147 (1) 43-70

3. UK experience of azacitidine therapy in patients with myelodysplastic syndromes. Leukaemia Research 2011, 35 (S1), 177a.

Dr Helen McCarthy, Consultant Haematologist, MBBS, PhD, MRCP, FRCPath

Clinical interests:

  • CLL
  • Myeloma.
  • Lymphoma (& Waldenstrom’s macroglobulinaemia) .
  • Autologous stem cell transplantation.
  • I completed a PhD working on tumour vaccination in CLL, Lymphoma & myeloma with Professor Stevenson. I then spent a year at the MD Anderson cancer centre, USA working on CLL prior becoming a consultant in 2006. I am committed to ongoing clinical and laboratory research to improve the outlook, quality of life and survival of patients.
  • Extensive portfolio of clinical trials for CLL, myeloma and lymphoma
  • Developed Velcade at home treatment
  • Chair of Regional Ethics Committee (Southampton MREC)
  • Expert witness for NICE appraisal in Follicular lymphoma
  • Member UK CLL forum, Myeloma Forum & lymphoma forum
  • Member of writing group for BSH National guidelines on Waldenstrom’s Macroglobulinaemia
  • Visiting faculty member at Bournemouth University (Centre for well being & Quality of Life)
  • Established BASCUP programme for haematology patients


1. McCarthy H, Wierda W, Barron L, Cromwell C, Wang J, Coombes K, Rangel R, Elenitoba-Johnson K, Keating M, Abruzzo L . High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood. June 2003 101 (12)

2. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-Idiotype vaccines (review). British Journal Haematology Nov 2003, 123, 770-781.

3. McCarthy H, Zhu D ,Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic hypermutation is a distinctive feature of follicular lymphoma. Blood 2002 April 1 99(7) 2562-8.

Prof David Oscier, Consultant Haematologist Honorary Senior Lecturer, Southampton University(since 1995)Visiting Professor, Bournemouth University(since 2008)

Clinical interests:

    • Member of the National Cancer Research Network CLL Trials committee.
    • Chairman of guidelines group of the UK CLL Forum.
    • Member of European Research Initiative in CLL.
    • Member of the International Splenic Lymphoma group.
  • Professor Oscier specialises in chronic lymphoproliferative disorders, especially chronic lymphocytic leukaemia (CLL). He is a member of the following groups:


    1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 No.6, 2069 2088.

    2. T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (6):1848-1854, 1999.

    3. D.G. Oscier, A.C. Gardiner, S.J. Mould, S. Glide, Z. Davis, R.E. Ibbotson, M.M. Corcoron, R.M. Chapman, P.W. Thomas, J.A. Copplestone, J.A. Orchard, and T.J. Hamblin. Loss or mutation of the p53 gene is an independent prognostic factor in chronic lymphocytic leukemia in patients with known V gene mutation status. Blood 100:1177-84, 2002.

    Dr Renata Walewska, Consultant Haematologist, MBChB, PhD, MRCP, FRCPath

    Clinical interests:

    Recently completed PhD in CLL with Prof Martin Dyer and joined the team in Bournemouth in 2010. Together with Prof Oscier and Dr McCarthy continues to develop her interest in CLL and lymphomas at Bournemouth.

    Proposed, developed and regularly updates these haematology webpages for the Trust.


    1. Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K (2009) Protein profiling of plasma membranes defines aberrant signalling pathways in mantle cell lymphoma. .Mol Cell Proteomics. 2009 Jul;8(7):1501-15. Epub 2009 Apr 2

    2. Walewska R, Boyd RS, Majid A, Jukes-Jones R, Cain K, Dyer MJ (2009) FAM129C a novel B cell protein is downregulated during CD40cell activation but not BCR stimulation. Poster accepted for presentation at the BSH 49th Annual Scientific Meeting, Brighton, April 2009

    3. Walewska R, Majid A , Tsoulakis O. , Gesk S , Siebert R, Kennedy DB , and Dyer MJS. (2007) BCL2 expression in chronic lymphocytic leukemia (CLL): lack of association with the BCL2 -938A>C promoter single nucleotide polymorphism (SNP). Blood. 111(2):874